06/12/2025
Prof. Dr. Wolfgang Janni (University Hospital Ulm ) shares key takeaways from his talk on liquid biopsy in breast cancer at GAWC 2025.
In the metastatic setting, liquid biopsy is already part of routine clinical practice — helping identify predictive biomarkers such as PIK3CA and ESR1 mutations to guide therapy.
But what about early-stage breast cancer?
While not yet standard, ctDNA has shown strong potential to detect residual disease after primary treatment — and trials are ongoing for patients with molecular relapse. Results are expected soon.
📅 Don’t miss the next opportunity to be part of the conversation —
Join us in Istanbul, January 30–31, 2026 for the next Global Academy of Women’s Cancer.